TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD)

CUSIP: 88338N206

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
+1,087,880
Put/Call ratio
239%
SEC-reported price per share
$5.59
Number of holders
43
Value change
+$6,039,029
Number of buys
27
Open additional details 1 more signal available
Number of sells
10
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
11,627,985

Security key

88338N206

Report period

Q4 2022

Institutions

43

Top holders

10

Ownership snapshot

Top reported holders of TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
John C.k. Milligan IV
Disclosed value leader
John C.k. Milligan IV
Comparable rows
0/15
Latest evidence
30 Sep 2022
3/4/5 13F Highest disclosed value: $12,698,322 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

John C.k. Milligan IV has the largest disclosed position value at $12.7M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens John C.k. Milligan IV's linked filing trail.
Disclosed position value Top 5
John C.k. Milligan IV $12.7M
Hugh O'Dowd $11.42M
Rubric Capital Management LP $7.68M
Robert G. Finizio $5.31M
James Darecca $1.86M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
John C.k. Milligan IV
3/4/5
Secretary/CEO of subsidiary
—
mixed-class rows
$12,698,322
5,542,076 shares
mixed-class rows
— 10 May 2021
Hugh O'Dowd
3/4/5
Chief Executive Officer
—
mixed-class rows
$11,415,713
4,250,000 shares
mixed-class rows
— 31 Mar 2022
Rubric Capital Management LP
13F
Company
13F
—
denominator unverified
$7,682,000
1,156,953 shares
— 30 Sep 2022
Robert G. Finizio
3/4/5
CEO, Director
—
mixed-class rows
$5,305,888
2,240,000 shares
mixed-class rows
— 01 Jul 2021
James Darecca
3/4/5
Chief Financial Officer
—
mixed-class rows
$1,857,402
558,163 shares
mixed-class rows
— 10 Aug 2021
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$1,729,000
260,411 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
43
Shares
3,475,915
Rows available
43
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
29
Q4 2022 holders
43
Holder diff
14
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .